The study of of inhaled IBIO123 for Mild to Moderate COVID-19 Illness
The company Immune Biosolutions Inc is enrolling patients into the clinical trial investigating Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness.
This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.
The trial is designed to enroll male and female 18 Years and older and is being conducted in the FARMOVS, Bloemfontein, Free State, South Africa; Jongaie Research, Pretoria West, Gauteng, South Africa.
The study start date is September 29, 2021.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT052988133.
